Overview
- GRAIL disclosed on February 19, 2026 that its NHS‑Galleri screening trial did not meet its primary endpoint and that a longer follow-up would likely be needed.
- The market reacted sharply when the trial results surfaced, with GRAL shares plunging about 50.55% in one day and wiping out roughly $2.2 billion in market value.
- Several national plaintiffs’ firms have filed or announced securities class actions and are soliciting investors to join or move for lead‑plaintiff status before the August 4, 2026 deadline.
- Hagens Berman has opened a parallel investigation focused on when management knew the follow‑up period was inadequate and is actively seeking whistleblowers under the SEC program.
- No class has been certified yet, so investors must retain counsel or move for lead‑plaintiff to seek control of the case and to press for disclosure of the trial’s underlying data.